| CAS NO: | 2095128-17-7 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 2095128-17-7 |
| Canonical SMILES | O=C(C[C@@H](CCCOC1=CC=CC=C1CN2C(C)=CN=C2C3=CC=C(C=C3)OC(F)(F)F)C)O |
| 分子式 | C25H27F3N2O4 |
| 分子量 | 476.49 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | MA-0204 is a potent, highly selective PPARδ modulator with EC50s of 0.4, 7.9 and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) [1]. MA-0204 is >10,000-fold selective for activation of PPARδ over PPARα and PPARγ receptors. It has EC50s of 6,990 nM and more than 100,000 nM for human PPARα and PPARγ, respectively. MA-0204 exhibits high protein binding to mouse plasma, good permeability and low potential for efflux. C[1].MA-0204 (1.2-12 nM) improves fatty acid oxidation in DMD patient muscle myoblasts mice[1].MA-0204 (0.04-40 nM) engages target gene expression in DMD patient muscle myoblasts[1]. PPARδ (30, 100 mg/kg) increases target gene transcription in the muscle[1]. [1]. Lagu B, et al. Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD). ACS Med Chem Lett. 2018 Jul 31;9(9):935-940. |
m.cnreagent.com